Trans Genic Inc. (2342) AI Stock Analysis

• Market Cap: ¥4.52B
• Dividend Yield: N/A
• Average Volume (3M): 549.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -0.77%
• EPS Growth: -288.43%
• Country: JP
• Employees: 236
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 16,999,142
• 10 Day Avg. Volume: 1,508,680
• 30 Day Avg. Volume: 549,150
• PEG Ratio: <0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.23
• P/FCF Ratio: -37.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: ¥276.00 ▲(8.66% Upside)
• Action: Reiterated Date: 12/31/25
• Date: Action: Reiterated 12/31/25

The score is held down primarily by weak financial performance (declining revenue, losses, and negative free cash flow), partially offset by constructive technical strength with the price trading above key moving averages and a positive MACD. Valuation remains a risk signal given the negative P/E and lack of dividend support.

Positive Factors

Specialized Niche Offering

Trans Genic's focus on genetically engineered animal models targets a specialized, technical niche in drug discovery and biomedical research. This creates durable demand from pharmaceutical and academic customers, high switching costs, and a defensible revenue base tied to long product development cycles.

Negative Factors

Declining Revenue Trend

Recent revenue declines signal weakening demand or pricing pressure in its core research tools business. Persistent top-line contraction reduces scale benefits, constrains reinvestment in R&D and model capabilities, and raises execution risk for regaining profitable growth across the next several quarters.

Trans Genic Inc. Business Overview & Revenue Model

Company Description

Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis ser...

Read more

Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis ser...

How the Company Makes Money

null...

Trans Genic Inc. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	13.32B	13.01B	13.08B	11.43B	12.58B	11.05B
Gross Profit	2.28B	2.17B	2.25B	1.99B	3.84B	2.78B
EBITDA	76.02M	-64.37M	253.62M	158.37M	2.07B	1.15B
Net Income	-963.26M	-1.09B	4.08M	-409.67M	1.88B	546.29M
Balance Sheet
Total Assets	9.72B	9.59B	9.84B	10.68B	10.44B	8.93B
Cash, Cash Equivalents and Short-Term Investments	2.30B	2.56B	2.48B	3.46B	4.62B	3.03B
Total Debt	2.85B	2.58B	2.26B	2.43B	1.86B	2.06B
Total Liabilities	4.87B	4.73B	3.84B	4.56B	3.80B	3.89B
Stockholders Equity	4.79B	4.76B	5.89B	6.02B	6.53B	4.92B
Cash Flow
Free Cash Flow	0.00	-81.35M	-658.12M	-1.74B	1.26B	1.08B
Operating Cash Flow	0.00	94.10M	-392.45M	-1.43B	1.79B	1.22B
Investing Cash Flow	0.00	-287.85M	-280.93M	-216.02M	981.87M	48.43M
Financing Cash Flow	0.00	265.10M	-342.69M	484.98M	-1.18B	10.04M

Trans Genic Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 254.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Neutral. The current price of 254 is below the 20-day moving average (MA) of 267.85, below the 50-day MA of 285.90, and above the 200-day MA of 244.12, indicating a neutral trend. The MACD of -4.93 indicates Negative momentum. The RSI at 47.58 is Neutral, neither overbought nor oversold. The STOCH value of 64.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2342.

Trans Genic Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	58 Neutral	¥7.90B	59.41	―	1.24%	-14.78%	-95.53%
2342	56 Neutral	¥4.52B	-828.32	―	―	-0.77%	-288.43%
4978	56 Neutral	¥17.03B	120.78	―	―	1.24%	-33.41%
6190	56 Neutral	¥1.84B	6.09	―	―	-6.92%	-144.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7774	51 Neutral	¥24.20B	-34.16	―	―	-5.65%	-469.19%
7776	49 Neutral	¥11.31B	-8.14	―	―	-42.49%	-2.37%